These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29941651)

  • 1. TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam.
    Piccirilli A; Perilli M; Amicosante G; Conte V; Tascini C; Rossolini GM; Giani T
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
    Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
    Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
    Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
    Poirel L; Ortiz de la Rosa JM; Sadek M; Nordmann P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0003922. PubMed ID: 35315685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
    Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
    Ourghanlian C; Soroka D; Arthur M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
    Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
    Alm RA; Johnstone MR; Lahiri SD
    J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate.
    Thomson GK; Ayaz M; Lutes K; Thomson KS
    J Clin Microbiol; 2018 Jan; 56(1):. PubMed ID: 29046407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
    Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
    FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
    Perilli M; Celenza G; De Santis F; Pellegrini C; Forcella C; Rossolini GM; Stefani S; Amicosante G
    Antimicrob Agents Chemother; 2008 Mar; 52(3):915-9. PubMed ID: 18160520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
    Avery LM; Nicolau DP
    Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.
    Sy SK; Beaudoin ME; Zhuang L; Löblein KI; Lux C; Kissel M; Tremmel R; Frank C; Strasser S; Heuberger JA; Mulder MB; Schuck VJ; Derendorf H
    J Antimicrob Chemother; 2016 Jul; 71(7):1866-80. PubMed ID: 27107096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes.
    Poirel L; Mammeri H; Nordmann P
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4528-31. PubMed ID: 15561821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global distribution of bla
    Long H; Zhao F; Feng Y; Zong Z
    Int J Antimicrob Agents; 2024 May; 63(5):107141. PubMed ID: 38484805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.